Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Spinal surgery patients who say they were given an unsafe biologic that caused excess bone growth and constant, incurable pain have asked the Sixth Circuit to revive their case, which was thrown out by a lower court in part because it was disorganized.
Cravath Swaine & Moore LLP aided cardiovascular medical device company The Spectranetics Corp. in its €1.9 billion ($2.16 billion) sale to Netherlands-based health technology giant Royal Philips, an effort by the Dutch company to boost its image-guided therapy unit, that the pair announced Wednesday.
A French, private equity-backed medical diagnostic equipment manufacturer could sell for €2 billion or more, KKR will rake in £1.4 billion through the sale of its stake in a Norwegian software company, and Halliburton has its eye on a U.S. oilfield equipment supplier backed by billionaire George Kaiser.
A Delaware judge refused Wednesday to dismiss a suit against directors of biopharma firm Sorrento Therapeutics Inc. over allegedly self-serving stock grants following an asset transfer, saying it's on the defendants to prove that the transactions were fair.
The experience of the past decade simply has not borne out the U.S. Supreme Court dissent’s prediction that Leegin “will likely raise the price of goods at retail” and “create considerable legal turbulence as lower courts seek to develop workable principles,” says Michael Lockerby, co-leader of Foley & Lardner LLP's distribution and franchise practice group.